Medical Developments International
(ASX:MVP) has signed a agreement with the CSIRO to develop new manufacturing technologies for pharmaceutical products.
The healthcare company will invest up to $3 million in the project over three years.
The project aims to develop the next generation of manufacturing technologies to make “small molecule” pharmaceutical products, at a significantly reduced cost, with improved quality.
CSIRO says the project will also assist in the growth and global competitiveness of Australia’s manufacturing industry.
Shares in Medical Developments International
(ASX:MVP) traded 5.63 per cent higher on Friday to $5.07.
